Novo started 2020 on an excellent note, with Q1 CER sales growth of 14%. This was a function of the sustained uptick of GLP-1 and COVID-19-induced panic buying across segments. So far there have been no major manufacturing and/or supply chain effects of COVID-19, but management guides for delays in early-stage trials. While GLP-1 remains Novo’s key value proposition, lack of medium-term growth drivers should result in the limited upside being maintained.
07 May 2020
Impressive Q1 20, although partly driven by COVID-19 stocking
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Impressive Q1 20, although partly driven by COVID-19 stocking
Novo Nordisk A/S Class B (NNO2:WBO) | 0 0 2.2% | Mkt Cap: 611,927m
- Published:
07 May 2020 -
Author:
Surbhit Gupta -
Pages:
4
Novo started 2020 on an excellent note, with Q1 CER sales growth of 14%. This was a function of the sustained uptick of GLP-1 and COVID-19-induced panic buying across segments. So far there have been no major manufacturing and/or supply chain effects of COVID-19, but management guides for delays in early-stage trials. While GLP-1 remains Novo’s key value proposition, lack of medium-term growth drivers should result in the limited upside being maintained.